First-trimester maternal plasma cell-free fetal DNA and preeclampsia.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  American Journal of Obstetrics and Gynecology

• Publication date

  2009-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ajog.2009.05.025PMID 19631923
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre‐eclampsia

  2008cited by this paper
• The best approach for early prediction of fetal gender by using free fetal DNA from maternal plasma

  2008cited by this paper
• Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A

  2008cited by this paper
• Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre‐eclampsia

  2007cited by this paper
• Free fetal DNA is not increased before 20 weeks in intrauterine growth restriction or pre‐eclampsia

  2007cited by this paper
• Correlation of fetal DNA levels in maternal plasma with Doppler status in pathological pregnancies

  2006cited by this paper
• Optimized Real‐Time Quantitative PCR Measurement of Male Fetal DNA in Maternal Plasma

  2006cited by this paper
• Optimized real-time quantitative PCR measurement of male fetal DNA in maternal plasma.

  2005cited by this paper
• Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies

  2005cited by this paper
• Maternal deaths from anaesthesia. An extract from Why Mothers Die 2000-2002, the Confidential Enquiries into Maternal Deaths in the United Kingdom: Chapter 9: Anaesthesia.

  2005cited by this paper
• Parallel assessment of circulatory fetal DNA and corticotropin-releasing hormone mRNA in early- and late-onset preeclampsia.

  2005cited by this paper
• Fetal DNA in maternal plasma as a screening variable for preeclampsia. A preliminary nonparametric analysis of detection rate in low‐risk nonsymptomatic patients

  2004cited by this paper
• Cell‐free fetal DNA (SRY locus) concentration in maternal plasma is directly correlated to the time elapsed from the onset of preeclampsia to the collection of blood

  2004cited by this paper
• A third base pair for the polymerase chain reaction: inserting isoC and isoG.

  2004cited by this paper
• Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia.

  2004cited by this paper
• Nucleic acid analysis using an expanded genetic alphabet to quench fluorescence.

  2004cited by this paper
• Sex‐determining region Y levels in maternal plasma: Evaluation in abnormal pregnancy

  2004cited by this paper
• Cell-free fetal DNA in the plasma of pregnant women with severe fetal growth restriction.

  2003cited by this paper
• Subclassification of Preeclampsia

  2003cited by this paper
• Hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome as a complication of preeclampsia in pregnant women increases the amount of cell-free fetal and maternal DNA in maternal plasma and serum.

  2002cited by this paper
• Fetal DNA clearance from maternal plasma is impaired in preeclampsia.

  2002cited by this paper
• THE LEVELS OF CIRCULATORY FETAL DNA IN MATERNAL PLASMA ARE ELEVATED PRIOR TO THE ONSET OF PREECLAMPSIA

  2002cited by this paper
• ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002.

  2002cited by this paper
• The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia.

  2002cited by this paper
• Elevation in erythroblast count in maternal blood before the onset of preeclampsia.

  2001cited by this paper
• Quantitative Analysis of Fetal DNA in Maternal Plasma in Pathological Conditions Associated with Placental Abnormalities

  2001cited by this paper
• Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia.

  2001cited by this paper
• Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia.

  2001cited by this paper
• Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study.

  2001cited by this paper
• Predictors of neonatal outcome in women with severe preeclampsia or eclampsia between 24 and 33 weeks' gestation.

  2000cited by this paper
• Increased fetal erythroblasts in women who subsequently develop pre-eclampsia.

  2000cited by this paper
• Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia.

  1999cited by this paper
• Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre‐eclamptic pregnancies

  1998cited by this paper
• UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group.

  1998cited by this paper
• Disturbed Feto‐Maternal Cell Traffic in Preeclampsia

  1998cited by this paper
• Placental bed spiral arteries in the hypertensive disorders of pregnancy

  1991cited by this paper
• The classification and definition of the hypertensive disorders of pregnancy.

  1988cited by this paper
• Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants.

  1987cited by this paper
• Inadequate maternal vascular response to placentation in pregnancies complicated by pre‐eclampsia and by small‐for‐gestational age infants

  1986cited by this paper
• Statistical methods for assessing agreement between two methods of clinical measurement.

  1986cited by this paper
• The physiological response of the vessels of the placental bed to normal pregnancy.

  1967cited by this paper
• AKUFO AND IBARAPA.

  1965cited by this paper

• Maternal cell-free DNA in early pregnancy for preeclampsia screening: a systematic review

  2025cites this paper
• Low-Molecular-Weight Heparin in Preeclampsia: Effects on Biomarkers and Prevention: A Narrative Review

  2025cites this paper
• Cell‑free fetal DNA at 11‑13 weeks of gestation is not altered in complicated pregnancies

  2024cites this paper
• Predicting the onset of preeclampsia by longitudinal monitoring of metabolic changes throughout pregnancy with Raman spectroscopy

  2023cites this paper
• Obstetrical, perinatal and genetic outcomes associated with non-reportable prenatal cell free DNA screening results.

  2023cites this paper
• Could Fetal Fraction Index Affect Maternal Serum Biomarkers or Uterine Artery Pulsatility Index in the First Trimester?

  2023cites this paper
• Cell-free fetal DNA impairs trophoblast migration in a TLR9-dependent manner and can be reversed by hydroxychloroquine.

  2023cites this paper
• Inflammation in preterm birth: Novel mechanism of preterm birth associated with innate and acquired immunity.

  2022cites this paper
• DO THE LEVELS OF cffDNA FRACTION CHANGE IN PREGNANCIES WITH PLACENTAL PROBLEMS?

  2022cites this paper
• DO THE LEVELS OF cffDNA FRACTION CHANGE IN PREGNANCIES WITH PLACENTAL PROBLEMS? SERBEST FETAL DNA FRAKSİYONU PLASENTAL PROBLEMLERE BAĞLI GEBELİK SONUÇLARINDA DEĞİŞİR Mİ

  2022cites this paper
• Global Trends in Research on Cell-Free Nucleic Acids in Obstetrics and Gynecology during 2017–2021

  2022cites this paper
• At Preeclampsia Diagnosis, Total Cell‐Free DNA Concentration is Elevated and Correlates With Disease Severity

  2021cites this paper
• Association of Cell-Free Fetal DNA at 11-17 Weeks of Pregnancy and the Outcome of Pregnancy

  2021cites this paper
• Alteration of circulating cell‐free DNA level by external cephalic version: A potential biomarker for direct evaluation of placental damage

  2021cites this paper
• Sensitivity assessment of workflows detecting rare circulating cell-free DNA targets: A study design proposal

  2021cites this paper
• Innovations in Placental Pathology

  2021cites this paper
• Cell-Free Foetal DNA as a Useful Marker for Preeclampsia Prediction

  2021cites this paper
• Fetal fraction of cell free DNA in screening for hypertensive disorders at 11–13 weeks

  2021cites this paper
• Association between Levels of Total Cell-Free DNA and Development of Preeclampsia—A Literature Review

  2021cites this paper
• Pregnancy-Related Extracellular Vesicles Revisited

  2021cites this paper
• Aspectos genómicos, transcriptómicos y del diagnóstico en el síndrome de Down

  2020cites this paper
• Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction

  2020cites this paper
• Implications of non-invasive prenatal testing for identifying and managing high-risk pregnancies.

  2020cites this paper
• Maternal Serum sEndoglin and Cell-Free Fetal DNA as Probable Markers of Preeclampsia: A Study in Single Center, Egypt

  2019cites this paper
• Cell-Free Fetal DNA: A Novel Biomarker for Early Prediction of Pre-eclampsia and Other Obstetric Complications.

  2019cites this paper
• The potential of serum fetal DNA for early diagnosis of gestational trophoblastic disease

  2019cites this paper
• Noninvasive Approaches to Prenatal Diagnosis: Historical Perspective and Future Directions.

  2018cites this paper
• El ácido úrico como factor predictor de la preeclampsia

  2018cites this paper
• DEGUM, ÖGUM, SGUM and FMF Germany Recommendations for the Implementation of First-Trimester Screening, Detailed Ultrasound, Cell-Free DNA Screening and Diagnostic Procedures.

  2018cites this paper
• Association of Fetal Fraction of Cell-Free DNA and Hypertensive Disorders of Pregnancy

  2018cites this paper
• Implications of failure to achieve a result from prenatal maternal serum cell‐free DNA testing: a historical cohort study

  2018cites this paper
• Fetal-specific hypermethylated RASSF1A quantification in pregnancy

  2017cites this paper
• Marcadores clínicos, biofísicos y bioquímicos para la predicción de preeclampsia

  2017cites this paper
• Chapter Fourteen – Biomarkers in Preeclampsia

  2017cites this paper
• Risk of Pregnancy-Associated Stroke Across Age Groups in New York State.

  2016cites this paper
• Circulating Maternal Total Cell-Free DNA, Cell-Free Fetal DNA and Soluble Endoglin Levels in Preeclampsia: Predictors of Adverse Fetal Outcome? A Cohort Study

  2016cites this paper
• Cell-Free Fetal DNA for the Prediction of Pre-Eclampsia at the First and Second Trimesters: A Systematic Review and Meta-Analysis

  2016cites this paper
• Etiopathogenesis, prediction, and prevention of preeclampsia

  2016cites this paper
• Evaluation of fetal hypermethylated RASSF1A in pre-eclampsia and its relationship with placental protein-13, pregnancy associated plasma protein-A and urine protein.

  2016cites this paper
• Quantification of circulating cell free fetal DNA and cell free total DNA in normal pregnancy and in pregnancy-related hypertension in Black South African Women.

  2016cites this paper
• Adverse perinatal outcomes are more frequent in pregnancies with a low fetal fraction result on noninvasive prenatal testing

  2016cites this paper
• Sterile inflammation and pregnancy complications: a review.

  2016cites this paper
• Absolute first trimester cell‐free DNA levels and their associations with adverse pregnancy outcomes

  2016influential citation
• Influence of storage conditions and extraction methods on the quantity and quality of circulating cell-free DNA (ccfDNA): the SPIDIA-DNAplas External Quality Assessment experience

  2015cites this paper
• Genomic and proteomic investigation of preeclampsia.

  2015cites this paper
• Noninvasive nucleic acid-based approaches to monitor placental health and predict pregnancy-related complications.

  2015cites this paper
• Maternal plasma cell‐free DNA in the prediction of pre‐eclampsia

  2015cites this paper
• Quantification and Application of Potential Epigenetic Markers in Maternal Plasma of Pregnancies with Hypertensive Disorders

  2015cites this paper
• Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics

  2015cites this paper
• Fetal DNA in maternal plasma in preeclamptic pregnancies

  2015cites this paper
• Current controversies in prenatal diagnosis 2: prediction and prevention of adverse pregnancy outcomes requires a genomic rather than proteomic solution

  2015cites this paper
• Chapter 11 – Tests to Predict Preeclampsia

  2015cites this paper
• Fetal CNAPS – DNA/RNA

  2015cites this paper
• New predictive and diagnostic biomarkers for preeclampsia

  2015cites this paper
• Maternal smoking does not affect the amount of cell-free fetal DNA in maternal plasma during the 1st trimester of pregnancy

  2015cites this paper
• First trimester screening can predict adverse pregnancy outcomes

  2014influential citation
• Preeclampsia from a renal point of view: Insides into disease models, biomarkers and therapy.

  2014cites this paper
• Cell-free fetal DNA and pregnancy-related complications (Review)

  2014cites this paper
• Clinical applications of the latest molecular diagnostics in noninvasive prenatal diagnosis.

  2014cites this paper
• Can the quantity of cell‐free fetal DNA predict preeclampsia: a systematic review

  2014cites this paper
• COMPARING METHODS FOR ISOLATION OF CIRCULATING-DNA (C-DNA). IMPLICATION OF C-DNA AS BIOMARKER IN THE CANCER

  2014cites this paper
• Chemical Diagnostics: From Bench to Bedside

  2014influential citation
• Quantification of Maternal Serum Cell-Free Fetal DNA in Early-Onset Preeclampsia

  2013cites this paper
• DNA methylation studies of preeclampsia and related conditions

  2013cites this paper
• Hypermethylated RASSF1A in maternal plasma as a non-sex-dependent marker for monitoring of pre-eclampsia

  2013cites this paper
• Plasma circulating cell-free DNA and uteroplacental blood flow in pre-eclamptic patients

  2013cites this paper
• Circulating nucleic acids in plasma and serum: applications in diagnostic techniques for noninvasive prenatal diagnosis

  2013cites this paper
• RASSF1A in maternal plasma as a molecular marker of preeclampsia

  2013influential citation
• Identifying mild and severe preeclampsia in asymptomatic pregnant women by levels of cell‐free fetal DNA

  2013cites this paper
• Cell-free fetal DNA and adverse outcome in low risk pregnancies.

  2013cites this paper
• Maternal Plasma Cell-Free Fetal and Maternal DNA at 11-13 Weeks' Gestation: Relation to Fetal and Maternal Characteristics and Pregnancy Outcomes

  2013cites this paper
• Fetal hemoglobin in preeclampsia: a new causative factor, a tool for prediction/diagnosis and a potential target for therapy

  2013cites this paper
• [Uric acid and purine plasma levels as plausible markers for placental dysfunction in pre-eclampsia].

  2013cites this paper
• Fetal Nucleic Acids in Maternal Circulation: A Genetic Resource for Noninvasive Prenatal Diagnosis

  2013cites this paper
• Absolute and relative quantification of placenta-specific micrornas in maternal circulation with placental insufficiency-related complications.

  2012cites this paper
• [Modern methods of early screening for preeclampsia and pregnancy-induced hypertension--a review].

  2012cites this paper
• Fetal Fraction in Maternal Plasma Cell-Free DNA at 11–13 Weeks’ Gestation: Effect of Maternal and Fetal Factors

  2012cites this paper
• Further improvement in quantifying male fetal DNA in maternal plasma.

  2012cites this paper
• Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18.

  2012cites this paper
• The dysfunctional placenta epigenome: causes and consequences.

  2012cites this paper
• Extracellular Nucleic Acids in Maternal Circulation as Potential Biomarkers for Placental Insufficiency

  2012influential citation
• Noninvasive prenatal diagnosis of Down syndrome: current knowledge and novel insights

  2012cites this paper
• Levosimendan reduces plasma cell-free DNA levels in patients with ischemic cardiomyopathy

  2011cites this paper
• Mass spectrometric based analysis, characterization and applications of circulating cell free DNA isolated from human body fluids.

  2011cites this paper
• The role of p53 modulation in correcting aberrant placental apoptosis in pre-eclampsia and IUGR

  2011cites this paper
• Placental Microparticles, DNA, and RNA in Preeclampsia

  2011cites this paper
• Cell-free nucleic acids as potential markers for preeclampsia.

  2011cites this paper
• Biomarkers in Preeclampsia

  2011cites this paper
• Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies?

  2011cites this paper
• Maternal Serum α-Fetoprotein at 11–13 Weeks’ Gestation in Spontaneous Early Preterm Delivery

  2011cites this paper
• Cell-free fetal nucleic acids as prenatal biomarkers.

  2011cites this paper
• Cribado combinado del primer trimestre para la predicción de la preeclampsia en gestantes con factores de alto riesgo

  2011cites this paper
• MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer

  2011cites this paper
• Circulating nucleic acids in cancer and pregnancy.

  2010cites this paper
• Placental Apoptosis in Health and Disease

  2010cites this paper
• Tests to Predict Preeclampsia

  2009cites this paper
• Analysis of the Relationship between Total Cell-Free DNA and Hypertensive Disorders of Pregnancy using an Epigenetic Marker

  2008influential citation